Bellerophon Therapeutics (NASDAQ:BLPH) Coverage Initiated by Analysts at StockNews.com

StockNews.com initiated coverage on shares of Bellerophon Therapeutics (NASDAQ:BLPH) in a report published on Thursday. The brokerage issued a hold rating on the biotechnology company’s stock.

Bellerophon Therapeutics Price Performance

NASDAQ BLPH opened at $0.04 on Thursday. Bellerophon Therapeutics has a 1 year low of $0.03 and a 1 year high of $0.46. The company has a fifty day moving average price of $0.04 and a 200-day moving average price of $0.05. The firm has a market cap of $428,155.00, a price-to-earnings ratio of -0.04 and a beta of 0.73.

About Bellerophon Therapeutics

Bellerophon Therapeutics, Inc, a clinical-stage therapeutics company, focuses on the development of products for the treatment of cardiopulmonary diseases in the United States. Its primary product is INOpulse, a proprietary pulsatile nitric oxide delivery platform for the treatment of pulmonary hypertension.